Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    ...
    14
    ...
ATC Name B/G Ingredients Dosage Form Price
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated 49,522,064 L.L
C10AA05 ATOR MEDIS G Atorvastatin - 20mg 20mg Tablet, film coated 591,291 L.L
A02BA03 FAMODAR 40 G Famotidine - 40mg 40mg Tablet, film coated 552,319 L.L
A06AX05 RESOLOR B Prucalopride succinate - 2mg 2mg Tablet, film coated 5,251,736 L.L
A10BH01 JANUVIA B Sitagliptin - 100mg 100mg Tablet, film coated 1,884,067 L.L
B01AF01 RIXALTA 10 G Rivaroxaban - 10mg 10mg Tablet, film coated 671,921 L.L
C10AA05 ATORLIP 20 G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,279,850 L.L
G04BE03 VIGOR-50 G Sildenafil (citrate) - 50mg 50mg Tablet, film coated 332,761 L.L
N06AB05 SEROXAT B Paroxetine (HCl) - 20mg 20mg Tablet, film coated 1,586,205 L.L
A02BA03 FAMONOR G Famotidine - 40mg 40mg Tablet, film coated 439,436 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 2mg 2mg Tablet, film coated 2,956,454 L.L
A10BH01 SAGIFOR G Sitagliptin (HCl monohydrate) - 100mg 100mg Tablet, film coated 1,242,606 L.L
B01AF01 VAROXA G Rivaroxaban - 10mg 10mg Tablet, film coated 2,879,854 L.L
C02KX01 TRACTAN G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated 47,747,570 L.L
C10AA05 ATORVA TAD G Atorvastatin - 20mg 20mg Tablet, film coated 1,087,169 L.L
J01CR02 AUGMENTIN B Amoxicillin (trihydrate) - 250mg, Clavulanic Acid (potassium) - 125mg 375mg Tablet, film coated 490,503 L.L
L01ED04 ALUNBRIG B Brigatinib - 30mg 30mg Tablet, film coated 119,936,249 L.L
L02BX03 ZYTIGA B Abiraterone acetate - 500mg 500mg Tablet, film coated 69,627,132 L.L
A06AX05 RESOLOR B Prucalopride succinate - 1mg 1mg Tablet, film coated 3,273,600 L.L
B01AF01 XAVIRAN G Rivaroxaban - 10mg 10mg Tablet, film coated 606,649 L.L
C02KX01 TRACLEER B Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated 79,583,961 L.L
G04BE03 VONTA G Sildenafil citrate - 50mg 50mg Tablet, film coated 335,961 L.L
L01ED04 ALUNBRIG B Brigatinib - 90mg 90mg Tablet, film coated 359,811,073 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 1mg 1mg Tablet, film coated 2,015,764 L.L
B01AF01 ZARLAN G Rivaroxaban - 10mg 10mg Tablet, film coated 1,439,255 L.L
C02KX01 TRACLEER B Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated 79,583,961 L.L
G04BE03 VONTA G Sildenafil citrate - 50mg 50mg Tablet, film coated 90,037 L.L
L01ED04 ALUNBRIG B Brigatinib - 180mg 180mg Tablet, film coated 474,793,952 L.L
L02BX03 APO-ABIRATERONE G Abiraterone acetate - 500mg 500mg Tablet, film coated 46,110,590 L.L
B01AF02 ELIQUIS B Apixaban - 5mg 5mg Tablet, film coated 4,183,603 L.L
    ...
    14
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025